TB Antigen Panel Assays for Accurate Antibody Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current tuberculosis (TB) diagnostic methods, such as smears, cultures, and tuberculin skin tests, are cumbersome, require specialized facilities and expertise, and have limitations in resource-poor settings, while serological assays for TB-specific antibodies lack accuracy and clinical utility.
Innovation Solution
The use of specific Mycobacterium tuberculosis proteins (Rv0222, Rv3120, Rv1989c, Rv3118, Rv1636, and Rv3426) or their immunogenic peptides in diagnostic tools like lateral flow rapid tests and enzyme-linked immunoassays to detect TB-specific antibodies in bodily fluids, providing improved sensitivity and specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional TB diagnostic methods (smears, cultures, TST) are used, then TB detection can be performed, but the procedures are cumbersome, require specialized facilities and expertise, and are time-consuming
Solution Approach 1:
The patent extracts the essential diagnostic function from complex laboratory procedures by using recombinant antigens (ESAT-6, CFP-10, and novel antigens Rv0222, Rv3120, Rv1989c, Rv3118, Rv1636, Rv3426) that can be detected through simpler immunological assays. This extraction allows TB detection to be performed without requiring full smear microscopy facilities, culture laboratories, or skilled personnel for TST interpretation
Solution Approach 2:
The patent introduces recombinant protein antigens as intermediaries between the complex traditional diagnostic methods and simple detection assays. These antigens serve as mediators that enable detection of TB-specific immune responses through ELISA, lateral flow, or other immunological tests, bridging the gap between accurate diagnosis and operational simplicity
2Measurement precision
If T-cell based assays (IGRAs) are used to improve TB diagnosis accuracy, then sensitivity and specificity are enhanced, but laboratory intensive requirements and resource needs increase
Solution Approach 1:
The patent replaces the complex cellular mechanism of T-cell based IGRAs with a simpler antibody-based detection mechanism. Instead of requiring live T-cell stimulation and interferon-gamma measurement, the patent uses recombinant antigens to detect TB-specific antibodies through immunological assays, substituting a mechanically simpler detection system that maintains diagnostic accuracy
Solution Approach 2:
The patent employs recombinant protein antigens that can be produced cost-effectively and used in disposable test formats such as lateral flow strips or single-use ELISA plates. This approach eliminates the need for expensive, complex laboratory equipment and reagents required by IGRAs, making the test suitable for resource-limited settings
3Ease of operation
If serological assays for TB-specific antibodies are used, then invasiveness is reduced and time requirements are minimized, but accuracy and clinical utility are insufficient
Solution Approach 1:
The patent develops a panel of recombinant antigens (ESAT-6, CFP-10, and novel antigens Rv0222, Rv3120, Rv1989c, Rv3118, Rv1636, Rv3426) that can be used across multiple assay formats including ELISA, lateral flow immunoassay, and other serological tests. This universal antigen panel maintains high diagnostic accuracy while enabling the test to be performed in various formats from complex laboratory assays to simple point-of-care devices
Solution Approach 2:
The patent creates a composite antigen panel combining multiple recombinant proteins that work together to enhance diagnostic accuracy. This composite approach uses several antigens in combination rather than relying on a single antigen, thereby improving sensitivity and specificity while maintaining the simplicity of serological testing
4Reliability
If tuberculin skin test is used for latent TB diagnosis, then detection capability is provided, but two clinic visits and skilled personnel are required
Solution Approach 1:
The patent extracts the diagnostic capability from the multi-visit TST process by using recombinant antigens that can detect TB-specific antibodies in a single blood draw. This extraction eliminates the need for two clinic visits (one for test administration, one for result interpretation) and removes the requirement for skilled personnel to perform skin test placement and reading
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These diagnostic tools offer a more accurate, less invasive, and user-friendly method for TB detection, reducing laboratory dependence and ambiguity in result interpretation, suitable for resource-poor settings.
Implementation Method 1
The use of specific Mycobacterium tuberculosis proteins (Rv0222, Rv3120, Rv1989c, Rv3118, Rv1636, and Rv3426) or their immunogenic peptides in diagnostic tools like lateral flow rapid tests and enzyme-linked immunoassays to detect TB-specific antibodies in bodily fluids
Data Source
AI summary
The present invention provides a method of detecting antibodies in a sample from a subject, wherein the antibodies bind to epitopes of Mycobacterium tuberculosis antigens, comprising contacting the sample with two or more isolated polypeptides or antigenic fragments or variants thereof, wherein the polypeptides comprise polypeptides selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, and 15; and detecting formation of antibody-peptide complexes comprising said isolated polypeptides or antigenic fragments or variants thereof, wherein formation of said complexes is indicative of the presence of the antibodies to epitopes of Mycobacterium tuberculosis antigens in said sample.